Αποτελέσματα Αναζήτησης
Some of the most common blood thinners include apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa, Lixiana), enoxaparin (Lovenox), heparin, rivaroxaban (Xarelto), warfarin (Jantoven), aspirin, clopidogrel (Plavix), dipyridamole (Persantine), prasugrel (Effient), and ticagrelor (Brilinta).
- Atrial Fibrillation
Atrial fibrillation (AFib) is an irregular heartbeat often,...
- Atrial Fibrillation
21 Δεκ 2022 · Brilinta (generic name: ticagrelor) is an oral antiplatelet prescription tablet for adults that is usually taken twice a day, in the morning and the evening. It is classified as a P2Y 12 inhibitor and works by making your platelets less sticky to help prevent blood clots from forming.
12 Ιουν 2024 · Official answer. Yes, a generic for Brilinta has been approved by the FDA. The generic medicine name for Brilinta is ticagrelor. Generic ticagrelor 90mg from the manufacturer Hisun Pharm Hangzhou has been approved by the FDA on January 23, 2019 but is not available in pharmacies yet.
20 Ιουλ 2011 · A generic version of Brilinta has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Brilinta and have been approved by the FDA: ticagrelor tablet;oral. Manufacturer: ALKEM LABS LTD.
17 Μαΐ 2024 · Common Brand Name(s): Brilinta; Common Generic Name(s): ticagrelor; Pronunciation: brih-LIN-tah; Drug Classes: antiplatelet; P2Y12 platelet inhibitor; Availability: prescription only; no...
8 Ιαν 2022 · Brilinta (ticagrelor) is a brand-name prescription drug used to prevent cardiovascular events and blood clots. Learn about side effects, dosage, and more.
9 Απρ 2024 · Brilinta (ticagrelor) is a blood-thinner used to reduce cardiovascular death and heart attack in patients with acute coronary syndromes (ACS). Brilinta works by preventing the formation of new blood clots , thus maintaining blood flow in the body to help reduce the risk of another cardiovascular event.
